Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• p53 protein inactivation is a common feature in lung carcinomas.
• Restoring p53 function is a key therapeutic goal, but current activators have limited efficacy within tumors.

Purpose of the Study:

• To identify and characterize novel small molecules capable of restoring p53 function in EGFR-driven lung cancer.
• To evaluate the therapeutic potential of identified compounds in preclinical models.

Main Methods:

• Established a p53 activator screening assay in EGFR-driven lung cancer cells.
• Utilized high-throughput compound screening to identify MX-C4.
• Assessed MX-C4's efficacy and toxicity in various cancer and normal cell lines, and in EGFR-driven xenograft models.
• Investigated the molecular mechanisms of MX-C4 action, including p53 phosphorylation, binding, and downstream effects on apoptosis and cell cycle.

Main Results:

• Identified MX-C4 as a small molecule that effectively promotes p53 phosphorylation at serine-392.
• MX-C4 demonstrated potent antitumor activity across multiple cancer cell lines with limited toxicity to normal cells and p53-null cells.
• Demonstrated p53-dependent anticancer activity, involving cell cycle arrest at G2/M phase and apoptosis induction via mitochondrial pathways.
• Showed significant tumor suppression in EGFR-driven xenograft models with effective in-tumor p53 activation and no obvious toxicity.

Conclusions:

• MX-C4 is a promising candidate for lung cancer therapy by restoring p53 function.
• The compound activates p53, leading to apoptosis and cell cycle arrest, and demonstrates efficacy in preclinical models.
• Restoring p53 function via MX-C4 represents a viable therapeutic strategy for lung cancer.